Adamis Pharma Sells Epinephrine Injector Rights to Novartis

Mark terry | July 2, 2018

article image
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.Although financial details were not released, Novartis’ Sandoz division will pay Adamis an upfront fee and various performance-based milestone payments. Net profits in the U.S. will be shared equally by Adamis and Sandoz.Adamis is holding rights to commercialize Symjepi outside the U.S., although under the deal, Sandoz has the first right of negotiation for those territories. The company indicates it may continuing developing Symject for other product candidates, including a naloxone product candidate being developed to treat opioid overdoses.In mid-2017, the U.S. Food and Drug Administration (FDA) approved the Symjepi 0.3-milligram injector. Adamis said it planned to market it as a low-cost alternative to existing products, which likely meant EpiPen. The deal with Sandoz also covers the Symjepi 0.15-milligram injector when, or if, it is approved by the FDA.

Spotlight

Velesco Pharmaceutical Services

Velesco applies nimblocity to your early stage drug development projects, with our proven formulation of expertise, flexibility, dedication, and velocity to clinic.

OTHER ARTICLES

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Spotlight

Velesco Pharmaceutical Services

Velesco applies nimblocity to your early stage drug development projects, with our proven formulation of expertise, flexibility, dedication, and velocity to clinic.

Events